Patients who develop eruptive keratoacanthomas (KAs) in the setting of PD-1/PD-L1 inhibitor–induced dermatitis are challenging to treat and discontinue immunotherapy at a much higher rate than those without KAs.^1-4 We successfully used 3 different nonsurgical anti-inflammatory therapies to treat both immunotherapy-induced dermatitis and concomitant eruptive KAs.

中文翻译：

---

PD-1 / PD-L1抑制剂引起的皮炎的治疗可解决伴随的爆发性角棘皮瘤。

在PD-1 / PD-L1抑制剂引起的皮炎的情况下发展为爆发性角膜棘皮瘤（KAs）的患者，与没有KAs的患者相比，治疗和中断免疫疗法的挑战性更高。^{1 -4}我们成功地使用了3种不同的非手术抗炎治疗方法，以治疗免疫治疗引起的皮炎和随之而来的爆发性KA。